Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Return on Capital Employed of 51.52% for Q1 2026, down 549.0% year-over-year from 11.47% in Q1 2025, and up 5.9% on a QoQ basis from 54.75% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 13 years of Return on Capital Employed data on file, last reported at 51.52% in Q1 2026.
- Quarterly Return on Capital Employed fell 549.0% year-over-year to 51.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.52% (down 549.0% YoY) and the FY2025 annual result came in at 47.2%, down 71.0% from the prior year.
- Return on Capital Employed climbed to 51.52% in Q1 2026 per RARE's latest filing, from 54.75% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 32.02% in Q1 2022 and bottomed at 60.99% in Q2 2023.
- The 5-year median for Return on Capital Employed is 49.73% (2025), against an average of 49.52%.
- The widest annual swing landed in 2023, when Return on Capital Employed plunged 2145 bps; it then soared 1667 bps in 2024.
- Tracing RARE's Return on Capital Employed over 5 years: stood at 49.13% in 2022, then fell by 7 bps to 52.48% in 2023, then advanced by 13 bps to 45.55% in 2024, then decreased by 20 bps to 54.75% in 2025, then rose by 6 bps to 51.52% in 2026.
- Per Business Quant, the three latest RARE Return on Capital Employed figures stand at 51.52% (Q1 2026), 54.75% (Q4 2025), and 59.9% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -51.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.52% |
| Dec 31, 2025 | -54.75% |
| Sep 30, 2025 | -59.90% |
| Jun 30, 2025 | -49.73% |
| Mar 31, 2025 | -46.03% |
| Dec 31, 2024 | -45.55% |
| Sep 30, 2024 | -41.41% |
| Jun 30, 2024 | -46.11% |
| Mar 31, 2024 | -50.30% |
| Dec 31, 2023 | -52.48% |
| Sep 30, 2023 | -58.07% |
| Jun 30, 2023 | -60.99% |
| Mar 31, 2023 | -53.47% |
| Dec 31, 2022 | -49.13% |
| Sep 30, 2022 | -48.77% |
| Jun 30, 2022 | -41.59% |
| Mar 31, 2022 | -32.02% |
| Dec 31, 2021 | -28.87% |
| Sep 30, 2021 | -27.54% |
| Jun 30, 2021 | -23.51% |
| Mar 31, 2021 | -20.37% |
| Dec 31, 2020 | -24.93% |
| Mar 31, 2020 | -45.13% |
| Dec 31, 2019 | -46.90% |
| Sep 30, 2019 | -50.66% |
| Jun 30, 2019 | -43.12% |
| Mar 31, 2019 | -46.95% |
| Dec 31, 2018 | -55.63% |
| Sep 30, 2018 | -52.56% |
| Jun 30, 2018 | -49.88% |
| Mar 31, 2018 | -59.60% |
| Dec 31, 2017 | -83.94% |
| Sep 30, 2017 | -75.28% |
| Jun 30, 2017 | -62.03% |
| Mar 31, 2017 | -53.79% |
| Dec 31, 2016 | -53.03% |
| Sep 30, 2016 | -52.13% |
| Jun 30, 2016 | -44.10% |
| Mar 31, 2016 | -35.13% |
| Dec 31, 2015 | -26.72% |
| Sep 30, 2015 | -24.23% |
| Jun 30, 2015 | -25.87% |
| Mar 31, 2015 | -25.87% |
| Dec 31, 2014 | -29.58% |
| Sep 30, 2014 | -28.10% |
| Jun 30, 2014 | -26.01% |
| Mar 31, 2014 | -32.80% |